Latest Orgenesis Inc (ORGS) Headlines Orgenes
Post# of 20
Posted On: 03/10/2014 10:10:10 PM
Latest Orgenesis Inc (ORGS) Headlines
Orgenesis Secures $3 Million in Funding From Kodiak Capital Group
Marketwire - Wed Dec 18, 10:02AM CST
Orgenesis, Inc. (OTCQB: ORGS), a development-stage company with a novel regenerative medicine technology that converts a diabetes patient's liver cells into functioning insulin-producing cells, has entered into a $3 million common stock purchase agreement with Kodiak Capital Group LLC, a Newport Beach, Calif.-based institutional investor.
Orgenesis CSO & Founder, Dr. Sarah Ferber, to Present at the 2013 World Stem Cell Summit on December 4
Marketwire - Tue Dec 03, 4:05PM CST
Orgenesis, Inc. (OTCQB: ORGS), a development-stage company with a novel regenerative medicine technology that converts a diabetes patient's liver cells into functioning insulin-producing cells, has been invited to present at the 2013 World Stem Cell Summit on Wednesday, December 4, 2013 at the Manchester Grand Hyatt in San Diego.
Orgenesis Establishes Belgium Subsidiary for Manufacturing Process Development of Clinical Grade Cells
Marketwire - Tue Nov 05, 7:31AM CST
Orgenesis, Inc. (OTCQB: ORGS), a development-stage company with a novel regenerative medicine technology that converts a diabetes patient's liver cells into functioning insulin-producing cells, has established and registered a subsidiary in Belgium, named Orgenesis SPRL, to complete process development and enable product manufacturing of cells to be used for clinical trials in Europe.
Orgenesis to Present at the 2013 Gateway Conference on September 10
Marketwire - Wed Sep 04, 4:16PM CDT
Orgenesis, Inc. (OTCBB: ORGS), a development-stage company with a novel therapeutic technology dedicated to converting a patient's own liver cells into functioning insulin-producing cells as a treatment for diabetes, has been invited to present at the 2013 Gateway Conference being held on Tuesday, September 10, 2013 at the Palace Hotel in San Francisco.
Dr. David Sidransky Appointed to Orgenesis' Board of Directors
GlobeNewswire - Thu Jul 18, 1:00PM CDT
Orgenesis Inc. (OTCBB:ORGS) ("Orgenesis" or the "Company"), a development-stage company with a novel therapeutic technology dedicated to converting a patient's own liver cells into functioning insulin-producing cells as a treatment for diabetes, is pleased to announce the appointment of Dr. David Sidransky, Professor and Director of the Head and Neck Cancer Research Division at the Johns Hopkins University School of Medicine's Department of Otolaryngology, to its Board of Directors.
Orgenesis to Present Updates at Two Key June Conferences
GlobeNewswire - Thu May 30, 1:30PM CDT
Orgenesis Inc. (OTCBB:ORGS) ("Orgenesis" or the "Company"), a development-stage company with a novel therapeutic technology dedicated to converting a patient's own liver cells into functioning insulin-producing cells as a treatment for diabetes, is pleased to announce that it will be presenting updates on the Company's business and technology at two key conferences in the month of June.
Orgenesis and ATMI Enter Into Process Development Agreement
GlobeNewswire - Thu May 09, 6:55AM CDT
Orgenesis Inc. (OTCBB:ORGS) ("Orgenesis" or the "Company"), a development-stage company with a novel therapeutic technology dedicated to converting a patient's own liver cells into functioning insulin-producing cells as a treatment for diabetes, announced today that its wholly owned subsidiary, Orgenesis Ltd., has entered into a process development agreement (the "PD Agreement") with ATMI, Inc. (Nasdaq:ATMI), a global technology company and leader in single-use bioprocess solutions.
Leading Diabetes Expert, Jay S. Skyler, M.D., Joins Orgenesis' Scientific Advisory Board
GlobeNewswire - Thu Apr 11, 7:15AM CDT
Orgenesis Inc. (OTCBB:ORGS) ("Orgenesis" or the "Company"), a development-stage company with a novel therapeutic technology dedicated to converting a patient's own liver cells into functioning insulin-producing cells as a treatment for diabetes, is pleased to announce the appointment of Jay S. Skyler, M.D., to its Scientific Advisory Board.
Orgenesis to Present at ATTD 2013
GlobeNewswire - Wed Feb 20, 1:11PM CST
Orgenesis Inc. (OTCBB:ORGS) ("Orgenesis" or the "Company"), a development-stage company with a novel therapeutic technology dedicated to converting a patient's own liver cells into functioning insulin-producing cells as a treatment for diabetes, is pleased to announce that its Chief Science Officer, Prof. Sarah Ferber, is scheduled to present at the 6 International Conference on Advanced Technologies & Treatments for Diabetes, to be held February 27 - March 3, 2013 in Paris, France.
Orgenesis Announces Management Changes
GlobeNewswire - Mon Jan 07, 7:00AM CST
Orgenesis Inc. (OTCBB:ORGS) ("Orgenesis" or the "Company"), a development-stage company with a novel therapeutic technology dedicated to converting a patient's own liver cells into functioning insulin-producing cells as a treatment for diabetes, announced today the appointment of Sav DiPasquale as President and Chief Executive Officer. Mr. DiPasquale succeeds Jacob BenArie, who has been appointed Chief Executive Officer of the Company's private subsidiary, Orgenesis Ltd.
Orgenesis Secures $3 Million in Funding From Kodiak Capital Group
Marketwire - Wed Dec 18, 10:02AM CST
Orgenesis, Inc. (OTCQB: ORGS), a development-stage company with a novel regenerative medicine technology that converts a diabetes patient's liver cells into functioning insulin-producing cells, has entered into a $3 million common stock purchase agreement with Kodiak Capital Group LLC, a Newport Beach, Calif.-based institutional investor.
Orgenesis CSO & Founder, Dr. Sarah Ferber, to Present at the 2013 World Stem Cell Summit on December 4
Marketwire - Tue Dec 03, 4:05PM CST
Orgenesis, Inc. (OTCQB: ORGS), a development-stage company with a novel regenerative medicine technology that converts a diabetes patient's liver cells into functioning insulin-producing cells, has been invited to present at the 2013 World Stem Cell Summit on Wednesday, December 4, 2013 at the Manchester Grand Hyatt in San Diego.
Orgenesis Establishes Belgium Subsidiary for Manufacturing Process Development of Clinical Grade Cells
Marketwire - Tue Nov 05, 7:31AM CST
Orgenesis, Inc. (OTCQB: ORGS), a development-stage company with a novel regenerative medicine technology that converts a diabetes patient's liver cells into functioning insulin-producing cells, has established and registered a subsidiary in Belgium, named Orgenesis SPRL, to complete process development and enable product manufacturing of cells to be used for clinical trials in Europe.
Orgenesis to Present at the 2013 Gateway Conference on September 10
Marketwire - Wed Sep 04, 4:16PM CDT
Orgenesis, Inc. (OTCBB: ORGS), a development-stage company with a novel therapeutic technology dedicated to converting a patient's own liver cells into functioning insulin-producing cells as a treatment for diabetes, has been invited to present at the 2013 Gateway Conference being held on Tuesday, September 10, 2013 at the Palace Hotel in San Francisco.
Dr. David Sidransky Appointed to Orgenesis' Board of Directors
GlobeNewswire - Thu Jul 18, 1:00PM CDT
Orgenesis Inc. (OTCBB:ORGS) ("Orgenesis" or the "Company"), a development-stage company with a novel therapeutic technology dedicated to converting a patient's own liver cells into functioning insulin-producing cells as a treatment for diabetes, is pleased to announce the appointment of Dr. David Sidransky, Professor and Director of the Head and Neck Cancer Research Division at the Johns Hopkins University School of Medicine's Department of Otolaryngology, to its Board of Directors.
Orgenesis to Present Updates at Two Key June Conferences
GlobeNewswire - Thu May 30, 1:30PM CDT
Orgenesis Inc. (OTCBB:ORGS) ("Orgenesis" or the "Company"), a development-stage company with a novel therapeutic technology dedicated to converting a patient's own liver cells into functioning insulin-producing cells as a treatment for diabetes, is pleased to announce that it will be presenting updates on the Company's business and technology at two key conferences in the month of June.
Orgenesis and ATMI Enter Into Process Development Agreement
GlobeNewswire - Thu May 09, 6:55AM CDT
Orgenesis Inc. (OTCBB:ORGS) ("Orgenesis" or the "Company"), a development-stage company with a novel therapeutic technology dedicated to converting a patient's own liver cells into functioning insulin-producing cells as a treatment for diabetes, announced today that its wholly owned subsidiary, Orgenesis Ltd., has entered into a process development agreement (the "PD Agreement") with ATMI, Inc. (Nasdaq:ATMI), a global technology company and leader in single-use bioprocess solutions.
Leading Diabetes Expert, Jay S. Skyler, M.D., Joins Orgenesis' Scientific Advisory Board
GlobeNewswire - Thu Apr 11, 7:15AM CDT
Orgenesis Inc. (OTCBB:ORGS) ("Orgenesis" or the "Company"), a development-stage company with a novel therapeutic technology dedicated to converting a patient's own liver cells into functioning insulin-producing cells as a treatment for diabetes, is pleased to announce the appointment of Jay S. Skyler, M.D., to its Scientific Advisory Board.
Orgenesis to Present at ATTD 2013
GlobeNewswire - Wed Feb 20, 1:11PM CST
Orgenesis Inc. (OTCBB:ORGS) ("Orgenesis" or the "Company"), a development-stage company with a novel therapeutic technology dedicated to converting a patient's own liver cells into functioning insulin-producing cells as a treatment for diabetes, is pleased to announce that its Chief Science Officer, Prof. Sarah Ferber, is scheduled to present at the 6 International Conference on Advanced Technologies & Treatments for Diabetes, to be held February 27 - March 3, 2013 in Paris, France.
Orgenesis Announces Management Changes
GlobeNewswire - Mon Jan 07, 7:00AM CST
Orgenesis Inc. (OTCBB:ORGS) ("Orgenesis" or the "Company"), a development-stage company with a novel therapeutic technology dedicated to converting a patient's own liver cells into functioning insulin-producing cells as a treatment for diabetes, announced today the appointment of Sav DiPasquale as President and Chief Executive Officer. Mr. DiPasquale succeeds Jacob BenArie, who has been appointed Chief Executive Officer of the Company's private subsidiary, Orgenesis Ltd.
(0)
(0)Orgenesis, Inc. (ORGS) Stock Research Links
Scroll down for more posts ▼